(EMAILWIRE.COM, October 17, 2018 ) The Global Newborn Screening Market, by Product Type (Assay Kits, Hearing Screening Devices, Mass Spectrometer, and Pulse Oximetry), by Application (Blood Spot Disease, Critical Congenital Cardiac Disease, Maple Syrup Urine Disease, Hearing Disability, Sickle Cell Disease, and Thyroid Disorder), by Test (Blood Test, Cardiac Test, Hearing Test, and Urine Test), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 561.5 million in 2018, and is projected to exhibit a CAGR of 12.4% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.
Newborn screening tests look for developmental, metabolic, and genetic disorders in infants. It allows steps to be taken before development of symptoms. Although, majority of these illnesses are very rare, they can be treated with early diagnosis. Newborn screening includes over 30 conditions and illnesses. Increasing awareness among parents for disease screening is a major factor driving newborn screening market growth. Furthermore, various government and non-government organizations are actively focused on offering better fetal and maternal care. For instance, in June 2018, the American Society of Hematology (ASH) led a campaign to fight sickle cell disease in Africa and urged governments, particularly in sub-Saharan Africa, to invest in newborn screening of the disease.
Request a Sample Copy:http://www.coherentmarketinsights.com/insight/request-sample/2192
Novel treatments, biomarkers, and technologies are expected to enable various diseases to be considered as potential candidates to be included in New Born Screening (NBS) programs. For instance, new treatments such as Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and gene therapy and new pharmacological drugs have allowed autoimmune diseases to be considered as potential candidates to be included in NBS programs.
Browse 22 Market Data Tables and 26 Figures spread through 167 Pages and in-depth TOC on “Newborn Screening Market, by Product Type (Assay Kits, Hearing Screening Devices, Mass Spectrometer, and Pulse Oximetry), by Application (Blood Spot Disease, Critical Congenital Cardiac Disease, Maple Syrup Urine Disease, Hearing Disability, Sickle Cell Disease, and Thyroid Disorder), by Test (Blood Test, Cardiac Test, Hearing Test, and Urine Test), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”
To know the latest trends and insights related to new born screening test market, click the link below:
http://www.coherentmarketinsights.com/market-insight/newborn-screening-market-2192
Manufacturer in the newborn screening market are focused on developing new test kits and devices in order to diagnose more diseases or disorders at birth. For instance, in February 2018, Sema4, a health information company offering advanced genomic testing, launched Sema4 Natalis, a supplemental newborn screening test designed to detect 193 childhood-onset diseases or disorders.
Furthermore, several governments are supporting manufacturers to develop new screening tests by relaxing regulations for manufacturing and marketing products. For instance, in February 2017, the U.S. FDA approved marketing of the Seeker System for the screening of four, rare Lysosomal Storage Disorders (LSDs) in newborns. The Seeker system is designed to detect Fabry, Gaucher, Mucopolysaccharidosis Type I (MPS I), and Pompe. It is the first newborn screening test permitted to be marketed by the FDA for these disorders.
Key Takeaways of the Newborn Screening Market:
The global newborn screening market is expected to expand at a CAGR of 12.4% during the forecast period (2018 2026), owing to increasing government support for newborn screening. According to National Institute of Health, NBS programs across the U.S., screen around four million infants, annually. This public health program detects treatable disorders in newborns, allowing treatment to begin often before symptoms or permanent problems occur.
Among product type, assay kits segment is expected to hold major revenue share in 2018, owing to increasing number of blood tests being conducted and blood samples stored for future use.
Major players operating in the global newborn screening market include, Agilent Technologies, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., and ZenTech S.A.
Pareesh Phulkar
8087996871
pareesh@coherentmarketinsights.com
Source: EmailWire.Com 
http://emailwire.com/release/940791-Newborn-Screening-Market-to-Surpass-US-13-Billion-by-2026.html
